IRLAB Receives Positive Feedback from EMA Confirming Alignment with FDA on Phase III Program for Mesdopetam
GOTHENBURG, SWEDEN / ACCESS Newswire / February 20, 2025 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, 20 ...